Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
What’s Your Call?
Collective community sentiment on Coral Laboratories Ltd
Your Vote -
Buy
40.00%
Hold
20.00%
Sell
40.00%
40.00%
5 users have voted
Option Chain
Analyzes market sentiment, predicts Coral Laboratories Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Coral Labs. - Notice Convening The 43Rd Annual General Meeting (AGM) And The Annual Report For Financial Year 2024-2025.
-
Coral Labs. - Reg. 34 (1) Annual Report.
-
Coral Labs. Q1 net profit down 70.91% at Rs 2.56 cr
-
Coral Labs. - Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association
-
Coral Labs. - Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
-
Coral Labs. - Outcome Of Board Meeting Held On August 13, 2025
-
Coral Labs. - Board Meeting Outcome for Outcome Of Board Meeting Held On August 13, 2025
-
Coral Labs. - Board Meeting Intimation for Under Regulation 29(1) Of Securities And Exchange Board Of India (Listing Obligati
-
Coral Labs. has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2025
-
Coral Labs. - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Key fundamentals
Evaluate the intrinsic value of Coral Laboratories Ltd stock
| Name | March-25 | March-24 | March-23 | March-22 | March-21 |
|---|---|---|---|---|---|
| Assets | 204.7645 | 177.4966 | 154.7981 | 162.0922 | 142.8974 |
| Liabilities | 204.7645 | 177.4966 | 154.7981 | 162.0922 | 142.8974 |
| Equity | 3.5726 | 3.5726 | 3.5726 | 3.5726 | 3.5726 |
| Gross Profit | 26.2394 | 16.2389 | 3.8117 | 8.2142 | 15.8492 |
| Net Profit | 24.1556 | 15.789 | 6.4454 | 9.0457 | 13.5546 |
| Cash From Operating Activities | -1.2223 | -5.4646 | 12.6652 | 6.0837 | 1.1169 |
| NPM(%) | 21 | 18.87 | 8.25 | 11.96 | 14.03 |
| Revenue | 115.0053 | 83.6605 | 78.1185 | 75.6107 | 96.5673 |
| Expenses | 88.7659 | 67.4216 | 74.3068 | 67.3965 | 80.7181 |
| ROE(%) | 11.86 | 7.75 | 3.16 | 4.44 | 6.65 |
Corporate Action
| XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
|---|
Peers
Other companies within the same industry or sector that are comparable to Coral Laboratories Ltd
| Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
|---|---|---|---|---|---|---|
| Albert David Ltd | 801.00 | -1.01 | 72.72 | 298.29 | 301.39 | 0.62 |
| Lotus Eye Hospital and Institute Ltd | 119.50 | -2.85 | 389.61 | 1086.92 | 3.55 | 0.00 |
| Bharat Immunological and Biologicals Corporation Ltd | 22.01 | 0.23 | 0.00 | 2256.80 | -39.50 | 0.00 |
| Astec Lifesciences Ltd | 823.00 | -1.44 | 0.00 | 1024.99 | -604.77 | 0.00 |
Company Info
Coral Laboratories P Ltd was incorporated on 19.6.1981 and was then converted into a Public Ltd company vide special resolution passed by the shareholders at the meeting held on 9th March 93. The company proposes to manufacture various pharmaceuticals formulations like tablets, capsules, dry syrups, liquieds and ointments and the company has not undertaken any commercial or business activity till date. The company has been promoted by Mr. N B Doshi, Chairman & Managing Director of the company. 2000 - Received WHO GMP Certificate for Baroda Plant. - Received ISO 9002 Certificate of Quality System Assessment issued by American Quality Assessors. 2001 - Entered in Global Marketing and started Exporting to Sri Lanka, Papua New Guinea, Cambodia and Kenya. - Renewal of WHO - GMP Certificate. 2002 - Entered into New Global Markets such as Ghana, Malawi, Nigeria, Lesotho, Ukraine and Vietnam. 2003 - Manufacturing Unit approved by (NAFDAC) Nigeria Food & Drug Administration. 2004 - Daman manufacturing unit started manufacturing since March 2004. This manufacturing unit is design to acquirer U.S. FDA & U.K. MHRA Certification. - Established a Quality Management System that is in compliance with the International Quality System Standard ISO 9001: 2008 Certificate Certificate No: IN015692. 2005 - Received WHO - GMP Certificate for Daman Plant. Manufacturing Unit No. 3 under construction at Dehradun. - Started Contract Manufacturing for ACI Pharm - USA and Medicale Pharmaceutique- France for their exports. - Recd ISO 9001-2008 Certificate for Daman plant. 2006 - Started Dehra Doon plant having facility to manufacture Tablets, Capsules, Liquids, Ointments, Lotion, Dry Syrup, Injectables(Dry Powder). 2009 - Received WHO GMP Certificate for Dehradun Plant. 2011 -Coral Laboratories Ltd has recommended dividend @ 15% i.e. Rs. 1.50 per Equity Shares of Rs. 10/-. 2012 -Coral Laboratories Ltd has recommended Dividend @ 15 % i.e. Rs. 1.50/-. per equity share of Rs. 10/- each. 2013 -Coral Laboratories Ltd has recommended Final Dividend @ 15 % i.e. Rs. 1.50/- per equity share of Rs. 10/- each 2014 -Coral Laboratories Ltd has recommended Dividend @ 20% i.e. Rs. 2/- per equity share of Rs. 10/- each.
Coral Laboratories P Ltd was incorporated on 19.6.1981 and was then converted into a Public Ltd company vide special resolution passed by the shareholders at the meeting held on 9th March 93. The company proposes to manufacture various pharmaceuticals formulations like tablets, capsules, dry syrups, liquieds and ointments and the company has not undertaken any commercial or business activity till date. The company has been promoted by Mr. N B Doshi, Chairman & Managing Director of the company. 2000 - Received WHO GMP Certificate for Baroda Plant. - Received ISO 9002 Certificate of Quality System Assessment issued by American Quality Assessors. 2001 - Entered in Global Marketing and started Exporting to Sri Lanka, Papua New Guinea, Cambodia and Kenya. - Renewal of WHO - GMP Certificate. 2002 - Entered into New Global Markets such as Ghana, Malawi, Nigeria, Lesotho, Ukraine and Vietnam. 2003 - Manufacturing Unit approved by (NAFDAC) Nigeria Food & Drug Administration. 2004 - Daman manufacturing unit started manufacturing since March 2004. This manufacturing unit is design to acquirer U.S. FDA & U.K. MHRA Certification. - Established a Quality Management System that is in compliance with the International Quality System Standard ISO 9001: 2008 Certificate Certificate No: IN015692. 2005 - Received WHO - GMP Certificate for Daman Plant. Manufacturing Unit No. 3 under construction at Dehradun. - Started Contract Manufacturing for ACI Pharm - USA and Medicale Pharmaceutique- France for their exports. - Recd ISO 9001-2008 Certificate for Daman plant. 2006 - Started Dehra Doon plant having facility to manufacture Tablets, Capsules, Liquids, Ointments, Lotion, Dry Syrup, Injectables(Dry Powder). 2009 - Received WHO GMP Certificate for Dehradun Plant. 2011 -Coral Laboratories Ltd has recommended dividend @ 15% i.e. Rs. 1.50 per Equity Shares of Rs. 10/-. 2012 -Coral Laboratories Ltd has recommended Dividend @ 15 % i.e. Rs. 1.50/-. per equity share of Rs. 10/- each. 2013 -Coral Laboratories Ltd has recommended Final Dividend @ 15 % i.e. Rs. 1.50/- per equity share of Rs. 10/- each 2014 -Coral Laboratories Ltd has recommended Dividend @ 20% i.e. Rs. 2/- per equity share of Rs. 10/- each.
Read More
Parent Organisation
Coral Laboratories Ltd.
Founded
06/02/1997
Managing Director
NSE Symbol
FAQ
The current price of Coral Laboratories Ltd is
The 52-week high for Coral Laboratories Ltd is
The market capitalization of Coral Laboratories Ltd is currently This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Coral Laboratories Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Coral Laboratories Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Coral Laboratories Ltd shares.
The CEO of Coral Laboratories Ltd is , who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.
